Castle Biosciences vs Exagen
CSTL and XGN side by side, both in health services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CSTL and XGN compare
Castle Biosciences is the larger company, worth 10 times as much as Exagen ($1.0B against $100M).
Exagen grew revenue faster over the last twelve months (13.7% versus 9.8% for Castle Biosciences).
Castle Biosciences keeps more of each dollar of sales as profit, with a net margin of −6.1% compared with −25.1% at Exagen.
Castle Biosciences scores higher on the StockData Score (11 against 4 for Exagen), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CSTL | XGN |
|---|---|---|
| Size and price | ||
| Market cap | $1.0B | $100M |
| Share price | $33.79 | $4.13 |
| Change, 1 year | −3.0% | −56.9% |
| Change, 5 years | −28.9% | −65.9% |
| Beta (5Y) | 1.38 | 1.18 |
| Employees | 883 | 220 |
| StockData Score | ||
| Total score | 11 (better) | 4 |
| Valuation score | 2 (better) | 0 |
| Growth score | 2 | 2 |
| Performance score | 3 (better) | 1 |
| Health score | 4 (better) | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 2.7× | 1.4× (better) |
| P/B | 2.2× (better) | 7.3× |
| P/FCF | 260× | – |
| FCF yield | 0.38% (better) | −13.0% |
| Fair value | $34.71 | $3.60 |
| Margin of safety | 2.6% (better) | −14.7% |
| Growth | ||
| Revenue growth (TTM) | 9.8% | 13.7% (better) |
| Revenue growth, 5Y average | 40.6% (better) | 9.7% |
| Profitability | ||
| Gross margin | 77.1% (better) | 58.7% |
| Operating margin | −7.4% (better) | −20.1% |
| Net margin | −6.1% (better) | −25.1% |
| FCF margin | 1.1% (better) | −18.0% |
| Return on equity | −4.9% (better) | −114% |
| Return on invested capital | −11.1% (better) | −167% |
| Financial health | ||
| Debt / equity | 0.02 (better) | 1.66 |
| Interest coverage | −51.2× | −2.9× (better) |
| Current ratio | 5.28 (better) | 3.46 |
| Altman Z-score | 6.63 (better) | −5.71 |
| Piotroski F-score | 4 | 4 |
| Dividends and buybacks | ||
| Dividend yield | 0.00% | – |
| Years of dividend growth | 0 | – |
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 89.5% | 34.1% |
| Held by insiders | 1.9% | 29.2% |
| Insider net buying, 12 months | −$18.3M | −$22.9K (better) |
| Short interest, % of float | 7.0% | 4.2% |
Go deeper
- CSTL stock overview
- CSTL income statement
- CSTL valuation and score
- XGN stock overview
- XGN income statement
- XGN valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.